Residency · Detroit, MI
Sponsored by Detroit Medical Center
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.
The New England journal of medicine · 2024 · 409 citations · Seema Sethi
Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.
The New England journal of medicine · 2025 · 114 citations · Seema Sethi
Assessing the contribution of rare variants to complex trait heritability from whole-genome sequence data.
Nature genetics · 2022 · 273 citations · Deepti Jain
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA.
Annals of oncology : official journal of the European Society for Medical Oncology · 2024 · 92 citations · Seema Sethi
Beyond the exome: What's next in diagnostic testing for Mendelian conditions.
American journal of human genetics · 2023 · 113 citations · Deepti Jain
Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021 · 214 citations ·
Squamous intraepithelial lesions (SIL: LSIL, HSIL, ASCUS, ASC-H, LSIL-H) of Uterine Cervix and Bethesda System.
CytoJournal · 2021 · 99 citations · Vinod Shidham
Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial.
The Lancet. Oncology · 2022 · 138 citations · Rashmi Tondon